玻璃体内注射贝伐单抗导致肾功能恶化和高血压失控。
Worsening of renal function and uncontrolled hypertension from intravitreal bevacizumab injections.
作者信息
Ahmed Moeed, Alouch Neil, Ahmed Arslan, Jagadesh Sunil K
机构信息
Department of Internal Medicine, Creighton University School of Medicine, Omaha, Nebraska.
Department of Pathology, Creighton University School of Medicine, Omaha, Nebraska.
出版信息
Proc (Bayl Univ Med Cent). 2021 Mar 1;34(4):527-529. doi: 10.1080/08998280.2021.1885285.
Abstract
Vascular endothelial growth factor (VEGF) inhibitors are used in the treatment of various cancers as well as diabetic retinopathy. The systemic use of these drugs has been associated with adverse effects such as worsening hypertension, proteinuria, and renal function. There have been some reported cases of worsening hypertension, thrombotic microangiopathy, or glomerular disease after intravitreal injections of bevacizumab, aflibercept, and ranibizumab. We present a case of a patient who was taking intravitreal bevacizumab injections for diabetic retinopathy and was hospitalized with worsening renal function, high blood pressure, and nephrotic-range proteinuria in the setting of tight glycemic control.
摘要
血管内皮生长因子（VEGF）抑制剂用于治疗各种癌症以及糖尿病性视网膜病变。这些药物的全身使用与诸如高血压恶化、蛋白尿和肾功能损害等不良反应相关。有一些报告称，玻璃体内注射贝伐单抗、阿柏西普和雷珠单抗后出现高血压恶化、血栓性微血管病或肾小球疾病的病例。我们报告一例患者，该患者因糖尿病性视网膜病变接受玻璃体内贝伐单抗注射治疗，在严格血糖控制的情况下，因肾功能恶化、高血压和肾病范围蛋白尿而住院。
相似文献
1
Worsening of renal function and uncontrolled hypertension from intravitreal bevacizumab injections.玻璃体内注射贝伐单抗导致肾功能恶化和高血压失控。
Proc (Bayl Univ Med Cent). 2021 Mar 1;34(4):527-529. doi: 10.1080/08998280.2021.1885285.
2
Intravitreal bevacizumab-induced exacerbation of proteinuria in diabetic nephropathy, and amelioration by switching to ranibizumab.玻璃体内注射贝伐单抗致糖尿病肾病蛋白尿加重，改用雷珠单抗后病情改善。
SAGE Open Med Case Rep. 2020 Feb 16;8:2050313X20907033. doi: 10.1177/2050313X20907033. eCollection 2020.
3
Thrombotic Microangiopathy and Acute Kidney Injury Induced After Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors VEGF Blockade-Related TMA After Intravitreal Use.玻璃体内注射血管内皮生长因子抑制剂后诱发的血栓性微血管病和急性肾损伤 玻璃体内使用后与VEGF阻断相关的血栓性微血管病
Front Med (Lausanne). 2020 Oct 7;7:579603. doi: 10.3389/fmed.2020.579603. eCollection 2020.
4
Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence.血管内皮生长因子抑制剂引起的肾毒性：新证据。
Kidney Int. 2019 Sep;96(3):572-580. doi: 10.1016/j.kint.2019.02.042. Epub 2019 Apr 9.
5
Worsening proteinuria and renal function after intravitreal vascular endothelial growth factor blockade for diabetic proliferative retinopathy.糖尿病性增殖性视网膜病变玻璃体腔内注射血管内皮生长因子阻滞剂后蛋白尿和肾功能恶化
Clin Kidney J. 2020 Jun 28;13(6):969-980. doi: 10.1093/ckj/sfaa049. eCollection 2020 Dec.
6
Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension.三名接受玻璃体内血管内皮生长因子抑制剂注射治疗的患者，随后出现慢性蛋白尿和高血压加重的情况。
Clin Kidney J. 2019 Feb;12(1):92-100. doi: 10.1093/ckj/sfy060. Epub 2018 Jul 27.
7
Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.两年内糖尿病视网膜病变的变化：比较阿柏西普、贝伐单抗和雷珠单抗的随机临床试验的二次分析
JAMA Ophthalmol. 2017 Jun 1;135(6):558-568. doi: 10.1001/jamaophthalmol.2017.0821.
8
Pathologic Correlation with Renal Dysfunction after Intravitreal Injections of Vascular Endothelial Growth Factor Antagonists.玻璃体内注射血管内皮生长因子拮抗剂后肾功能障碍的病理相关性
Ann Clin Lab Sci. 2021 Nov;51(6):875-882.
9
Intravitreal Antivascular Endothelial Growth Factor Therapy May Induce Proteinuria and Antibody Mediated Injury in Renal Allografts.玻璃体内抗血管内皮生长因子治疗可能会导致肾移植受者出现蛋白尿和抗体介导的损伤。
Transplantation. 2015 Nov;99(11):2382-6. doi: 10.1097/TP.0000000000000750.
10
CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.玻璃体腔内注射贝伐单抗、阿柏西普或雷珠单抗治疗糖尿病性黄斑水肿后血浆血管内皮生长因子水平的变化。
Retina. 2018 Sep;38(9):1801-1808. doi: 10.1097/IAE.0000000000002004.
引用本文的文献
1
Intravitreal vascular endothelial growth factor inhibitor systemic and renal toxicity registry.玻璃体内血管内皮生长因子抑制剂全身及肾脏毒性登记处。
Clin Kidney J. 2025 Jun 27;18(8):sfaf206. doi: 10.1093/ckj/sfaf206. eCollection 2025 Aug.
2
Systemic Effects of Intravitreal Anti-VEGF Therapy: A Review of Safety across Organ Systems.玻璃体内抗血管内皮生长因子治疗的全身效应：跨器官系统安全性综述
Ophthalmol Ther. 2025 Jun 6. doi: 10.1007/s40123-025-01157-4.
3
Checkpoint Inhibitor-Associated Scleroderma and Scleroderma Mimics.检查点抑制剂相关的硬皮病及硬皮病样疾病
Pharmaceuticals (Basel). 2023 Feb 8;16(2):259. doi: 10.3390/ph16020259.
4
The Association of Intravitreal Injections of Different Anti-Vascular Endothelial Growth Factor with Systemic Outcomes in Diabetic Patients.糖尿病患者玻璃体内注射不同抗血管内皮生长因子与全身预后的相关性
J Pers Med. 2023 Mar 18;13(3):544. doi: 10.3390/jpm13030544.
5
A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes.一项关于玻璃体内血管内皮生长因子抑制剂对心肾结局影响的系统评价和荟萃分析。
Nephrol Dial Transplant. 2023 Jun 30;38(7):1666-1681. doi: 10.1093/ndt/gfac305.
6
Pro- and anti-fibrotic effects of vascular endothelial growth factor in chronic kidney diseases.血管内皮生长因子在慢性肾脏病中的抗纤维化和促纤维化作用。
Ren Fail. 2022 Dec;44(1):881-892. doi: 10.1080/0886022X.2022.2079528.
本文引用的文献
1
Bevacizumab-induced immunoglobulin A vasculitis with nephritis: A case report.贝伐单抗诱发的免疫球蛋白A血管炎伴肾炎：一例报告。
Medicine (Baltimore). 2019 Nov;98(45):e17870. doi: 10.1097/MD.0000000000017870.
2
Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension.三名接受玻璃体内血管内皮生长因子抑制剂注射治疗的患者，随后出现慢性蛋白尿和高血压加重的情况。
Clin Kidney J. 2019 Feb;12(1):92-100. doi: 10.1093/ckj/sfy060. Epub 2018 Jul 27.
3
SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.玻璃体内注射阿柏西普、贝伐单抗和雷珠单抗的全身药代动力学和药效学
Retina. 2017 Oct;37(10):1847-1858. doi: 10.1097/IAE.0000000000001493.
4
Minimal change disease onset observed after bevacizumab administration.贝伐单抗给药后观察到微小病变病发作。
Clin Kidney J. 2016 Apr;9(2):239-44. doi: 10.1093/ckj/sfv139. Epub 2015 Dec 28.
5
Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center.与抗血管内皮生长因子（VEGF）相关的肾脏疾病：单中心8年观察性研究
Medicine (Baltimore). 2014 Nov;93(24):333-339. doi: 10.1097/MD.0000000000000207.
6
The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension.玻璃体腔内注射贝伐单抗（阿瓦斯汀）对全身高血压的影响。
Eye (Lond). 2009 Aug;23(8):1714-8. doi: 10.1038/eye.2008.360. Epub 2008 Dec 12.
7
VEGF inhibition and renal thrombotic microangiopathy.血管内皮生长因子抑制与肾血栓性微血管病
N Engl J Med. 2008 Mar 13;358(11):1129-36. doi: 10.1056/NEJMoa0707330.
8
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.血糖水平与2型糖尿病大血管及微血管并发症的关联（英国前瞻性糖尿病研究35）：前瞻性观察研究
BMJ. 2000 Aug 12;321(7258):405-12. doi: 10.1136/bmj.321.7258.405.
Zotero 插件